A Post-Market Clinical Follow-Up on Safety and Performance of the Ophthalmic Viscoelastic Devices Eyefill SC and Eyefill MB

Who May Qualify: - Adult subjects scheduled for cataract surgery with im-plantation of a posterior chamber intraocular lens; - Signed willing to sign a consent form; - Availability, willingness, ability, and sufficient cognitive awareness to comply with examination procedures Who Should NOT Join This Trial: - Known hypersensitivity to sodium hyaluronate; - Corneal endothelial cell density \<1500 cells/mm2; - Corneal abnormalities; - Cataract density of grade 4+; - Previous intraocular or corneal surgery; - Chronic or recurrent inflammatory eye diseases (e.g., iritis, scleritis, iridocyclitis, or rubeosis iridis); - Clinically significant, uncontrolled glaucoma with expected negative impact on visual acuity outcomes; - Ongoing systemic or ocular steroid therapy; - Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal or optic disorders) that are predicted to cause future acuity loss to 20/30 or worse in one or both eyes; - Active ocular or systemic infection (bacterial, viral, or fungal), including fever - Subjects who may be expected to require a combined or other secondary surgical procedure - Females of childbearing potential (those who are not surgically sterilized or not postmenopausal for at least 12 months) if they meet one of the following conditions: Pregnant, lactating or unwilling to use effective birth control over the course of the study; - Concurrent or previous (within 30 days) participation in another drug or device investigation. Always talk to your doctor about whether this trial is right for you.